Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development - 05/08/11
, J. Rick Turner, PhD b, Adel Nada, MD, MS c, Tara L. DiMino, MD a, Ivo Hynie, MD, PhD d, Robert Kleiman, MD e, Peter Kowey, MD f, Mitchell W. Krucoff, MD g, Jay W. Mason, MD h, Alex Phipps, PhD i, Christopher Newton-Cheh, MD, MPH j, Robert Pordy, MD k, Colette Strnadova, PhD d, Shari Targum, MD l, Kathleen Uhl, MD l, John Finkle, MD aRésumé |
This white paper, prepared by members of the Cardiac Safety Research Consortium, discusses several important issues regarding the evaluation of ventricular arrhythmias in early clinical pharmacology trials and their potential consequences for later clinical drug development. Ventricular arrhythmias are infrequent but potentially important medical events whose occurrence in early clinical pharmacology trials can dramatically increase safety concerns. Given the increasing concern with all potential safety signals and the resultant more extensive electrocardiographic monitoring of subjects participating in early phase trials, an important question must be addressed: Are relatively more frequent observations of ventricular arrhythmias related simply to more extensive monitoring, or are they genuinely related to the drug under development? The discussions in this paper provide current thinking and suggestions for addressing this question.
Le texte complet de cet article est disponible en PDF.Plan
| Prior presentation: The work described herein has not previously been publicly presented. |
|
| Disclaimer: Views expressed herein should not be construed as representing views or policies of the Food and Drug Administration or of Health Canada. |
Vol 159 - N° 5
P. 716-729 - mai 2010 Retour au numéro
Article précédent
- Resistance or resistors? Has Ohm's law come to antiplatelet therapy?
- Neal S. Kleiman
- Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): Rationale and design of a meta-analysis project
- Matthias W. Lorenz, Horst Bickel, Michiel L. Bots, Monique M.B. Breteler, Alberico L. Catapano, Moise Desvarieux, Bo Hedblad, Bernhard Iglseder, Stein Harald Johnsen, Michal Juraska, Stefan Kiechl, Ellisiv B. Mathiesen, Giuseppe D. Norata, Liliana Grigore, Joseph Polak, Holger Poppert, Maria Rosvall, Tatjana Rundek, Ralph L. Sacco, Dirk Sander, Matthias Sitzer, Helmuth Steinmetz, Eva Stensland, Johann Willeit, Jacqueline Witteman, David Yanez, Simon G. Thompson, The PROG-IMT Study Group t
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?